These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30412084)

  • 1. Choroidal thickness changes in non-treated acute and ranibizumab-treated chronic central serous chorioretinopathy.
    Yumusak E; Gokcinar NB; Ornek K
    Medicine (Baltimore); 2018 Oct; 97(43):e12885. PubMed ID: 30412084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Mineralocorticoid-Receptor Antagonists: Choroidal Parameters Changes Using OCT in Central Serous Chorioretinopathy.
    Faghihi H; Mohammadzadeh V; Nabavi A; Faghihi S; Kadivar S; Ghassemi F
    Ophthalmic Surg Lasers Imaging Retina; 2019 Nov; 50(11):726-733. PubMed ID: 31755972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal Bevacizumab and Ranibizumab in the Treatment of Acute Central Serous Chorioretihopathy: A Single Center Retrospective Study.
    Tekin K; Sekeroglu MA; Cankaya AB; Teke MY; Doguizi S; Yilmazbas P
    Semin Ophthalmol; 2018; 33(2):265-270. PubMed ID: 27841949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy.
    Gawęcki M; Jaszczuk-Maciejewska A; Jurska-Jaśko A; Kneba M; Grzybowski A
    BMC Ophthalmol; 2019 Jul; 19(1):160. PubMed ID: 31345183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macular ganglion cell complex thickness in acute and chronic central serous chorioretinopathy.
    Demirok G; Kocamaz F; Topalak Y; Altay Y; Sengun A
    Int Ophthalmol; 2017 Apr; 37(2):409-416. PubMed ID: 27324370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low incidence of pachydrusen in central serous chorioretinopathy in an Indian cohort.
    Singh SR; Chakurkar R; Goud A; Chhablani J
    Indian J Ophthalmol; 2020 Jan; 68(1):118-122. PubMed ID: 31856486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choroidal thickness and choroidal blood flow after intravitreal bevacizumab injection in eyes with central serous chorioretinopathy.
    Okamoto M; Matsuura T; Ogata N
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):25-32. PubMed ID: 25559505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subfoveal choroidal thickness changes after intravitreal bevacizumab therapy for central serous chorioretinopathy.
    Ünlü C; Erdogan G; Gezginaslan TA; Akcay BI; Kardes E; Bozkurt TK
    Arq Bras Oftalmol; 2016; 79(5):308-311. PubMed ID: 27982209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative evaluation of choriocapillaris using optical coherence tomography and optical coherence tomography angiography in patients with central serous chorioretinopathy after half-dose photodynamic therapy.
    Yang HS; Kang TG; Park H; Heo JS; Park J; Lee KS; Choi S
    PLoS One; 2020; 15(1):e0227718. PubMed ID: 31929582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choroidal thickness measurements during central serous chorioretinopathy treatment.
    Brandl C; Helbig H; Gamulescu MA
    Int Ophthalmol; 2014 Feb; 34(1):7-13. PubMed ID: 23572440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choroidal thickness measurement by enhanced depth imaging and swept-source optical coherence tomography in central serous chorioretinopathy.
    Hamzah F; Shinojima A; Mori R; Yuzawa M
    BMC Ophthalmol; 2014 Nov; 14():145. PubMed ID: 25421855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration.
    Yun C; Oh J; Ahn J; Hwang SY; Lee B; Kim SW; Huh K
    Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1693-702. PubMed ID: 26781585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choroidal Changes at the Leakage Site in Acute Central Serous Chorioretinopathy.
    Sahoo NK; Maltsev DS; Goud A; Kulikov AN; Chhablani J
    Semin Ophthalmol; 2019; 34(5):380-385. PubMed ID: 31257974
    [No Abstract]   [Full Text] [Related]  

  • 14. Intravitreal Brolucizumab for Chronic Central Serous Chorioretinopathy without Choroidal Neovascular Membrane - a Pilot Study.
    Ramamurthy SR; Behera UC; Narula R; Sadda SR; Narayanan R
    Semin Ophthalmol; 2024 Nov; 39(8):615-622. PubMed ID: 38270124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pattern electroretinography in patients with unilateral acute central serous chorioretinopathy.
    Doguizi S; Sekeroglu MA; Ozkoyuncu D; Yilmazbas P
    Clin Exp Optom; 2020 Sep; 103(5):656-662. PubMed ID: 31822040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study.
    Pitcher JD; Witkin AJ; DeCroos FC; Ho AC
    Br J Ophthalmol; 2015 Jun; 99(6):848-52. PubMed ID: 25595177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors predicting 2-year treatment results of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good baseline visual acuity.
    Mori R; Tanaka K; Yuzawa M
    Medicine (Baltimore); 2018 Jun; 97(25):e11188. PubMed ID: 29924037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series.
    Salz DA; Pitcher JD; Hsu J; Regillo CD; Fineman MS; Elliott KS; Vander JF; Fischer DH; Spirn MJ
    Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):439-44. PubMed ID: 25970864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
    Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
    Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
    Gharbiya M; Giustolisi R; Marchiori J; Bruscolini A; Mallone F; Fameli V; Nebbioso M; Abdolrahimzadeh S
    Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.